US BioDefense makes cardiac regeneration pact:
This article was originally published in Clinica
Executive Summary
US BioDefense has formed a heart tissue regeneration deal with the University of Texas MD Anderson Cancer Center that gives it the priority option to review and license patent pending technology regarding the use of non-marrow stem cell for cardiac regeneration. "The use of these stem cells for myocardial regeneration may prove to be superior to other stem cell sources by circumventing the pain and anaesthesia complications associated with bone marrow aspiration procedures," said David Chin, CEO of the City of Industry, California-based firm.
You may also be interested in...
PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca is it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: